美国潜伏性结核感染检测市场：市场规模、份额和趋势分析（按检测方法、应用、最终用途和地区划分），细分市场预测（2026-2033 年）

美国潜伏性结核感染检测市场概述

据估计，2025 年美国潜伏性结核病检测市场规模为 4.2761 亿美元，预计到 2033 年将达到 6.5111 亿美元，2026 年至 2033 年的复合年增长率为 5.17%。

结核病发病率上升的原因是潜伏性结核感染 (LTBI) 发展为活动性结核病感染的风险增加、扩大结核病诊断的资助计划以及诊断方法的技术进步。

根据美国疾病管制与预防中心 (CDC) 估计，美国有多达 1,300 万人感染了潜伏性结核病 (LTBI)，如果不进行治疗，大约 5% 到 10% 的感染者会在一生中的某个时候发展为活动性结核病。

此外，对结核病根除和预防医学日益重视，为潜伏性结核感染（LTBI）检测市场创造了强劲的成长机会。公共卫生部门日益认识到，美国大多数活动性结核病病例并非由近期感染引起，而是由潜伏性行为感染重新运作所致。因此，国家结核病根除策略正转向在潜伏性结核感染发展为活动性结核病之前对其进行识别和治疗，更加重视早期准确的诊断检测。

结核病的风险受多种因素影响，包括年龄、潜在疾病和暴露环境，老年人和某些特定环境的人口风险更高。因此，透过检测和治疗对潜伏性结核感染（LTBI）进行管理，对于降低发展为活动性结核病的风险和预防疾病传播至关重要。增加潜伏性结核感染发展为活动性结核病风险的因素包括：

目录

第一章：分析方法和范围

第二章执行摘要

第三章：美国潜伏性结核感染检测市场：影响因素、趋势与范围

• 市场历史及展望
  • 母市场展望（潜伏性结核感染检测市场）
  • 相关/附随市场展望（结核病诊断市场）
• 市场动态
• 美国潜伏性结核感染检测市场：分析工具
  • 产业分析：波特五力分析
  • PESTEL 分析
• 法律规范
• 救赎方案
• 移民测试的支付和报销
• 美国CLIA认证的检测实验室
  • 美国所有获得CLIA认证的检测实验室名单
  • 提供经 CLIA 和 NYS 认证的检查室名单，这些实验室可进行 QFT (CPT 86480)、T-SPOT.TB (86481) 和 TST (86580) 检测，并列出检测次数。
  • 按 NPI、地区和医疗专科列出医生名单和检验申请数量。

第四章：美国潜伏性结核感染检测市场：依检测类型分類的估算与趋势分析

• 美国潜伏性结核感染检测市场：波动分析（依检测类型划分）
• 美国潜伏性结核感染检测市场展望：依检测类型划分
• 市场规模、预测与趋势分析（2021-2033）：涵盖以下内容：
• 干扰素-γ释放试验（IGRA）
  • QFT
  • T. SPOT
• 结核菌素皮肤反应（TST）

第五章：美国潜伏性结核感染检测市场：按应用领域分類的估算与趋势分析。

• 美国潜伏性结核感染检测市场：波动分析（按应用领域划分）
• 美国潜伏性结核感染检测市场展望：按应用领域划分
• 市场规模、预测与趋势分析（2021-2033）：涵盖以下内容：
• 肺结核患者的家庭接触者
• 爱滋病毒感染者
• 其他的

第六章：美国潜伏性结核感染检测市场：依最终用途分類的估算与趋势分析

• 美国潜伏性结核感染检测市场：依最终用途分類的波动分析
• 美国潜伏性结核感染检测市场展望：依最终用途划分
• 市场规模、预测与趋势分析（2021-2033）：涵盖以下内容：
• 诊断和检测机构
• 医院/诊所
• 学术和研究机构

第七章 竞争情势

• 参与企业的分类
• 近期趋势及影响分析：依主要市场参与企业
• 企业市场占有率分析（2025 年）
• 主要企业公司简介
  • QIAGEN
  • Euroimmun US
  • bioMerieux
  • Oxford Immunotec
  • SD Biosensor, INC.
  • Quest Diagnostics
  • LabCorp
  • ARUP Laboratories
  • Mayo Clinic Laboratories
  • BioReference Laboratories
  • Par Pharmaceutical, Inc.

U.S. Latent Tuberculosis Infection Detection Market Summary

The U.S. latent tuberculosis infection detection market size was estimated at USD 427.61 million in 2025 and is projected to reach USD 651.11 million by 2033, growing at a CAGR of 5.17% from 2026 to 2033. This growth is driven by an increasing risk of developing active tuberculosis infection from latent tuberculosis infection (LTBI), growing funding programs to promote TB diagnosis, aided by technological advancements in diagnostic methods.

According to estimates from the Centers for Disease Control and Prevention (CDC), up to 13 million people in the U.S. are believed to have LTBI, and without preventive treatment, about 5 %-10 % of those infected will develop active TB at some point in their lives.

Moreover, the growing focus on tuberculosis (TB) elimination and preventive care is creating a strong growth opportunity for the LTBI detection market. Public health authorities increasingly recognize that most active TB cases in the U.S. result from reactivation of latent infection rather than recent transmission. As a result, national TB elimination strategies have shifted toward identifying and treating LTBI before it progresses to active disease, placing greater emphasis on early and accurate diagnostic testing.

The risk of incident TB is influenced by various factors, such as age, underlying health conditions, and exposure settings, with older individuals and those in certain environments facing higher risks. Hence, managing LTBI through testing and treatment is crucial in reducing the risk of developing active TB and preventing the spread of the disease. Factors contributing to increased susceptibility to active TB from LTBI include:

U.S. Latent Tuberculosis Infection Detection Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. latent tuberculosis infection detection market report based on test, application, and end use:

• Test Outlook (Revenue, USD Million, 2021 - 2033) (Volume, Number of Tests in Thousands)
  • Interferon Gamma Released Assay (IGRA)
  • QFT
  • T.SPOT
  • Tuberculin Skin Test (TST)
• Application Outlook (Revenue, USD Million, 2021 - 2033) (Volume, Number of Tests in Thousands)
  • Household Contacts With Pulmonary TB
  • PLHIV
  • Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033) (Volume, Number of Tests in Thousands)
  • Diagnostic Laboratories
  • Hospitals/Clinics
  • Academic & Research Institutions

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Segment Definitions
  • 1.2.1. Test
  • 1.2.2. Application
  • 1.2.3. End Use
  • 1.2.4. Estimates and forecasts timeline
• 1.3. Objectives
  • 1.3.1. Objective-1
  • 1.3.2. Objective-2
  • 1.3.3. Objective-3
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased database
  • 1.5.2. GVR's internal database
  • 1.5.3. Secondary sources
  • 1.5.4. Primary research
• 1.6. Information or Data Analysis
  • 1.6.1. Data analysis models
• 1.7. Market Formulation & Validation
• 1.8. Model Details
  • 1.8.1. Commodity flow analysis
    • 1.8.1.1. Approach 1: Commodity flow approach
    • 1.8.1.2. Approach 2: Country-wise market estimation using bottom-up approach
• 1.9. List of Secondary Sources
• 1.10. List of Primary Sources
• 1.11. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Test Snapshot
• 2.3. Application and End-use Snapshot
• 2.4. Competitive Insights

Chapter 3. U.S. Latent Tuberculosis Infection Detection Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook (Latent Tuberculosis Infection Detection Market)
  • 3.1.2. Related/ancillary market outlook (Tuberculosis Diagnostics Market)
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increase in risk of developing active Tuberculosis Infection from LTBI
    • 3.2.1.2. Increasing Funding Programs to Promote TB Diagnostics
    • 3.2.1.3. Technological Advancements in Diagnostics Methods
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Limited Awareness and Underdiagnosis of Latent TB
  • 3.2.3. Market Opportunity Analysis
    • 3.2.3.1. Growing Focus on TB Elimination and Preventive Care
    • 3.2.3.2. Expansion of Community-Based and Targeted Screening Programs
  • 3.2.4. Market Challenge Analysis
    • 3.2.4.1. Low Disease Visibility and Competing Public Health Priorities
• 3.3. U.S. Latent Tuberculosis Infection Detection Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitutes
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic landscape
    • 3.3.2.3. Social landscape
    • 3.3.2.4. Technological landscape
    • 3.3.2.5. Environmental landscape
    • 3.3.2.6. Legal landscape
• 3.4. Regulatory Framework
• 3.5. Reimbursement Scenario
• 3.6. Payment/ Reimbursement for Immigration Testing
• 3.7. CLIA Labs in the U.S.
  • 3.7.1. List of all the CLIA Labs in the U.S
  • 3.7.2. List of CLIA and NYS Certified Labs that Perform QFT (CPT 86480), T-SPOT.TB (86481), TST (86580), and their Volumes
  • 3.7.3. List of Physicians and Volumes Ordered of the Tests Split out by NPI, Geography, and Practice

Chapter 4. U.S. Latent Tuberculosis Infection Detection Market: Test Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. U.S. Latent Tuberculosis Infection Detection Market: Test Movement Analysis
• 4.3. U.S. Latent Tuberculosis Infection Detection Market by Test Outlook (USD Million)
• 4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033, for the following
• 4.5. Interferon Gamma Released Assay (IGRA)
  • 4.5.1. Interferon Gamma Released Assay (IGRA) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5.2. Interferon Gamma Released Assay (IGRA) Market Estimates and Forecasts, 2021 - 2033 (Number of Tests, in Thousands)
  • 4.5.3. QFT
    • 4.5.3.1. QFT Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.3.2. QFT Market Revenue Estimates and Forecasts, 2021 - 2033 (Number of Tests, in Thousands)
  • 4.5.4. T. SPOT
    • 4.5.4.1. T. SPOT Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.4.2. T. SPOT Market Revenue Estimates and Forecasts, 2021 - 2033 (Number of Tests, in Thousands)
• 4.6. Tuberculin Skin Test (TST)
  • 4.6.1. Tuberculin Skin Test (TST) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6.2. Tuberculin Skin Test (TST) Market Revenue Estimates and Forecasts, 2021 - 2033 (Number of Tests, in Thousands)

Chapter 5. U.S. Latent Tuberculosis Infection Detection Market: Application Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. U.S. Latent Tuberculosis Infection Detection Market: Application Movement Analysis
• 5.3. U.S. Latent Tuberculosis Infection Detection Market by Application Outlook (USD Million)
• 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033, for the following
• 5.5. Household Contacts With Pulmonary TB
  • 5.5.1. Household Contacts With Pulmonary TB Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5.2. Household Contacts With Pulmonary TB Market Revenue Estimates and Forecasts, 2021 - 2033 (Number of Tests, in Thousands)
• 5.6. PLHIV
  • 5.6.1. PLHIV Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6.2. PLHIV Market Revenue Estimates and Forecasts, 2021 - 2033 (Number of Tests, in Thousands)
• 5.7. Others
  • 5.7.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.7.2. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (Number of Tests, in Thousands)

Chapter 6. U.S. Latent Tuberculosis Infection Detection Market: End Use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. U.S. Latent Tuberculosis Infection Detection Market: End Use Movement Analysis
• 6.3. U.S. Latent Tuberculosis Infection Detection Market by End Use Outlook (USD Million)
• 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033, for the following
• 6.5. Diagnostic Laboratories
  • 6.5.1. Diagnostic Laboratories Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.2. Diagnostic Laboratories Market Revenue Estimates and Forecasts, 2021 - 2033 (Number of Tests, in Thousands)
• 6.6. Hospitals/Clinics
  • 6.6.1. Hospitals/Clinics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.2. Hospitals/Clinics Market Revenue Estimates and Forecasts, 2021 - 2033 (Number of Tests, in Thousands)
• 6.7. Academic & Research Institutions
  • 6.7.1. Academic & Research Institutions Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7.2. Academic & Research Institutions Market Revenue Estimates and Forecasts, 2021 - 2033 (Number of Tests, in Thousands)

Chapter 7. Competitive Landscape

• 7.1. Market Participant Categorization
• 7.2. Recent Developments & Impact Analysis by Key Market Participants
• 7.3. Company Market Share Analysis, 2025
• 7.4. Key Company Profiles
  • 7.4.1. QIAGEN
    • 7.4.1.1. Company overview
    • 7.4.1.2. Financial performance
    • 7.4.1.3. Product benchmarking
    • 7.4.1.4. Strategic initiatives
  • 7.4.2. Euroimmun US
    • 7.4.2.1. Company overview
    • 7.4.2.2. Financial performance
    • 7.4.2.3. Product benchmarking
    • 7.4.2.4. Strategic initiatives
  • 7.4.3. bioMerieux
    • 7.4.3.1. Company overview
    • 7.4.3.2. Financial performance
    • 7.4.3.3. Product benchmarking
    • 7.4.3.4. Strategic initiatives
  • 7.4.4. Oxford Immunotec
    • 7.4.4.1. Company overview
    • 7.4.4.2. Financial performance
    • 7.4.4.3. Product benchmarking
    • 7.4.4.4. Strategic initiatives
  • 7.4.5. SD Biosensor, INC.
    • 7.4.5.1. Company overview
    • 7.4.5.2. Financial performance
    • 7.4.5.3. Product benchmarking
    • 7.4.5.4. Strategic initiatives
  • 7.4.6. Quest Diagnostics
    • 7.4.6.1. Company overview
    • 7.4.6.2. Financial performance
    • 7.4.6.3. Product benchmarking
    • 7.4.6.4. Strategic initiatives
  • 7.4.7. LabCorp
    • 7.4.7.1. Company overview
    • 7.4.7.2. Financial performance
    • 7.4.7.3. Product benchmarking
    • 7.4.7.4. Strategic initiatives
  • 7.4.8. ARUP Laboratories
    • 7.4.8.1. Company overview
    • 7.4.8.2. Financial performance
    • 7.4.8.3. Product benchmarking
    • 7.4.8.4. Strategic initiatives
  • 7.4.9. Mayo Clinic Laboratories
    • 7.4.9.1. Company overview
    • 7.4.9.2. Financial performance
    • 7.4.9.3. Product benchmarking
    • 7.4.9.4. Strategic initiatives
  • 7.4.10. BioReference Laboratories
    • 7.4.10.1. Company overview
    • 7.4.10.2. Financial performance
    • 7.4.10.3. Product benchmarking
    • 7.4.10.4. Strategic initiatives
  • 7.4.11. Par Pharmaceutical, Inc.
    • 7.4.11.1. Company overview
    • 7.4.11.2. Financial performance
    • 7.4.11.3. Product benchmarking
    • 7.4.11.4. Strategic initiatives

List of Tables

• Table 1 List of secondary sources
• Table 2 List of abbreviations
• Table 3 List of all the CLIA labs in the U.S
• Table 4 List of CLIA and NYS certified labs that perform QFT (CPT 86480), T-SPOT.TB (86481), TST (86580), and their volumes
• Table 5 List of physicians and volumes ordered of the tests, split out by NPI, geography, and practice
• Table 6 U.S. latent tuberculosis infection detection market, by test, 2021 - 2033 (USD Million)
• Table 7 U.S. latent tuberculosis infection detection market, by application, 2021 - 2033 (USD Million)
• Table 8 U.S. latent tuberculosis infection detection market, by end use, 2021 - 2033 (USD Million)

List of Figures

• Fig. 1 U.S. latent tuberculosis infection detection market segmentation
• Fig. 2 Market research process
• Fig. 3 Data triangulation techniques
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Value chain-based sizing & forecasting
• Fig. 7 QFD modelling for market share assessment
• Fig. 8 Market formulation & validation
• Fig. 9 U.S. latent tuberculosis infection detection market snapshot
• Fig. 10 Test snapshot
• Fig. 11 Application and end-use snapshot
• Fig. 12 Competitive landscape snapshot
• Fig. 13 Parent market outlook
• Fig. 14 Related/ancillary market outlook
• Fig. 15 Market dynamics
• Fig. 16 Market driver analysis (current & future impact)
• Fig. 17 Market restraint analysis (current & future impact)
• Fig. 18 Porter's five forces analysis
• Fig. 19 SWOT analysis, by factor (political & legal, economic and technological)
• Fig. 20 U.S. latent tuberculosis infection detection market, test outlook key takeaways
• Fig. 21 U.S. latent tuberculosis infection detection market, test movement analysis
• Fig. 22 IGRA market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 23 IGRA market revenue estimates and forecasts, 2021 - 2033 (Number of Tests in Thousands)
• Fig. 24 Tuberculin Skin Test (TST) market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 25 Tuberculin Skin Test (TST) market revenue estimates and forecasts, 2021 - 2033 (Number of Tests in Thousands)
• Fig. 26 QFT market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 27 QFT market revenue estimates and forecasts, 2021 - 2033 (Number of Tests in Thousands)
• Fig. 28 T.SPOT market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 29 T.SPOT market revenue estimates and forecasts, 2021 - 2033 (Number of Tests in Thousands)
• Fig. 30 U.S. latent tuberculosis infection detection market, application outlook key takeaways
• Fig. 31 U.S. latent tuberculosis infection detection market, application movement analysis
• Fig. 32 Household Contacts with Pulmonary TB market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 33 Household Contacts with Pulmonary TB market revenue estimates and forecasts, 2021 - 2033 (Number of Tests in Thousands)
• Fig. 34 PLHIV market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 35 PLHIV market revenue estimates and forecasts, 2021 - 2033 (Number of Tests in Thousands)
• Fig. 36 Others market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 37 Others market revenue estimates and forecasts, 2021 - 2033 (Number of Tests in Thousands)
• Fig. 38 U.S. latent tuberculosis infection detection market, end use outlook key takeaways
• Fig. 39 U.S. latent tuberculosis infection detection market, end use movement analysis
• Fig. 40 Diagnostic Laboratories market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 41 Diagnostic Laboratories market revenue estimates and forecasts, 2021 - 2033 (Number of Tests in Thousands)
• Fig. 42 Hospitals/Clinics market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 43 Hospitals/Clinics market revenue estimates and forecasts, 2021 - 2033 (Number of Tests in Thousands)
• Fig. 44 Academic & Research Institutions market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 45 Academic & Research Institutions market revenue estimates and forecasts, 2021 - 2033 (Number of Tests in Thousands)
• Fig. 46 Key company categorization
• Fig. 47 Strategy mapping